



Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects

Rebecca E. Wrishko¹ · Jacqueline B. McCrea¹ · Ka Lai Yee¹ · Wen Liu¹ · Deborah Panebianco¹ · Eric Mangin¹ · Manu Chakravarthy¹ · Maria P. Martinez-Cantarín² · Walter K. Kraft²

Published online: 20 March 2019
© Springer Nature Switzerland AG 2019

Correction to: *Clinical Drug Investigation*
<https://doi.org/10.1007/s40261-019-00764-x>

The original version of this article unfortunately contained a mistake. Figure 1 was incorrect. The corrected Fig. 1 is given below.

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s40261-019-00764-x>.

✉ Jacqueline B. McCrea
jackie_mccrea@merck.com

¹ Merck & Co., Inc., Kenilworth, NJ, USA

² Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA




Fig. 1 Study design for **a** Study P008, **b** Study P038 diltiazem sub-study, and **c** Study P038 rifampin sub-study. *D* day, *h* hours